European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
NCT ID: NCT05041803
Last Updated: 2025-11-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
407 participants
INTERVENTIONAL
2021-10-19
2024-07-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
NCT03898479
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
NCT03137381
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
NCT04784533
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
NCT03941548
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
NCT03811912
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CTP-543
Patients who previously completed a qualifying CTP-543 clinical trial
CTP-543
Twice daily dosing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CTP-543
Twice daily dosing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
* Donation of blood at any point throughout the study and for 30 days after last dose of study medication
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Pharmaceutical Industries, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Dermatologie CHRU de Brest - Hopital Morvan
Brest, Finistere, France
Service de Dermatologie Centre Hospitalier Universitaire de Nice - Hopital Archet 2
Nice, Provence-Alpes-Côte d'Azur Region, France
CHU de Bordeaux, Hopital Saint-Andre
Bordeaux, , France
Hopital Saint-Louis - GH De La Rochelle-Re-Aunis
La Rochelle, , France
Hôpital La Timone-Dermatologie
Marseille, , France
Hopital de l'Hotel Dieu - CHU de Nantes
Nantes, , France
Hôpital Saint Louis, Centre de Santé Sabouraud
Paris, , France
Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
Toulouse, , France
Universitätsklinikum Tübingen Universitäts-Hautklinik
Tübingen, Baden-Wüttermberg, Germany
Universitätsklinikum Erlangen, Hautklinik
Erlangen, Bavaria, Germany
Klinikum Rechts der Isar, Technische Universität München, Hautklinik
München, Bavaria, Germany
Klinik für Dermatologie, Venerologie und Allergologie
Frankfurt am Main, Hesse, Germany
Fachklinik Bad Bentheim
Bad Bentheim, Lower Saxony, Germany
Klinik für Dermatologie und Venerologie, Zentrale Studienkoordination für innovative Dermatologie (ZiD)
Münster, North Rhine-Westphalia, Germany
Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin
Berlin, , Germany
Pecsi Tudomanyegyetem Klinikai Kozpont, Bor-, Nemikortani es Onkodermatologiai Klinika
Pécs, Baranya, Hungary
SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati es Allergologiai Klinika
Szeged, Csongrad-Csanad County, Hungary
Semmelweis Egyetem AOK, Bor-, Nemikortani es Boronkologiai Klinika
Budapest, Pest County, Hungary
Twoja Przychodnia Centrum Medyczne Nowa Sol
Nowa Sól, Lubusz Voivodeship, Poland
ETG Siedlce
Siedlce, Masovian Voivodeship, Poland
ETG Skierniewice
Skierniewice, Masovian Voivodeship, Poland
RCMed Oddzial w Sochaczewie
Sochaczew, Masovian Voivodeship, Poland
OT.CO Clinic Klinika Osipowicz & Turkowski sp. z o.o
Warsaw, Masovian Voivodeship, Poland
Carpe Diem Centrum Medycyny Estetycznej
Warsaw, Masovian Voivodeship, Poland
ETG Warszawa
Warsaw, Masovian Voivodeship, Poland
NZOZ Specjalistyczny Osrodek Dermatologiczny DERMAL
Bialystok, , Poland
Vita Longa Sp.Zo.O
Katowice, , Poland
Specjalistyczny Gabinet Dermatologiczny s.c.
Krakow, , Poland
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Szczecin, , Poland
My Clinic
Warsaw, , Poland
Royalderm Agnieszka Nawrocka
Warsaw, , Poland
WroMedica I. Bielicka, A. Strazalkowska s.c.
Wroclaw, , Poland
Hospital Clínic de Barcelona
Barcelona, Barcelona/Cataluña, Spain
Hospital del Mar
Barcelona, , Spain
Hospital de La Santa Creu i Sant Pau
Barcelona, , Spain
Hospital Universitario Reina Sofía
Córdoba, , Spain
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Hospital 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-002365-18
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CP543.5002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.